| Search by tag or site | Login to my blog ? Start my own blog |
![]() |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Exegenics: Dr.frost Continues His Hot Hand
Posted on 03/28/2007 18:23:28 | Link | Post Comment
by H.S. Ayoub
BioHealth Investor.com
Back in February, I recommended investing in Continucare (CNU) after doctor Phillip Frost, founder of Ivax Corporation, purchased shares of the healthcare company.
I also explained how it seemed that anything Dr.Frost touches turns into gold. His large purchase of shares of Ladenburg Thalmann Financial Services Inc (LTS) catapaulted the stock to multiple returns, and I continue to hold shares in LTS.
Just last Thursday, March 22nd, Dr.Frost and his group purchased controlling shares of Getting Ready Corporation (GTRY.OB) at around $1.25 a share. The stock ended trading on Tuesday at $2.99 a share!
Today, eXegenics (EXEG.OB), which Dr.Frost and his investment group invested in recently, announced that the empty shell company has agreed to merge with two eye disease biotech firms, and form a new company called Opko Corporation.
Opko will be headquartered in Miami, Dr.Frost's business stronghold, and will utilize Acuity Pharmaceuticals and Froptix Corporation's novel eye disease drug programs.
Acuity holds the rights to a drug that successfully completed Phase II clinical trials for wet age-related macular degeneration and diabetic macular edema.
Froptix has a number of drug candidates in preclinical development to treat dry age- related macular degeneration and other ophthalmic diseases. The company also intends to develop complimentary diagnostic tools.
Both companies were privately held.
What really was interesting in Exegenics' press release today was this statement, "...intends to apply to have its shares listed on the American Stock Exchange"
Shares of Exegenics closed Tuesday's trading session at $3.28 a share, after closing at $2.52 the day before. I purchased shares at $1.95 shortly after the closing of Dr.Frost's purchase a couple of months ago.
Here are Dr.Frost stocks I hold:
LTS
bought= $1.09
high= $3.74
CNU
bought= $3.03
high= $3.69
EXEG.OB
bought= $1.95
high= $3.29
Here are some stocks that Dr.Frost has purchased shares of which I do not hold in my portfolio:
Non-Invasive Monitoring Systems Inc.
(NIMU.OB)
Castle Brands
(ROX)
Cellular Technical Services Co.
(CTSC.OB)
Getting Ready Corporation
(GTRY.OB)
Source: BioHealhInvestor.com
_____________________
BioHealth Investor.com
Back in February, I recommended investing in Continucare (CNU) after doctor Phillip Frost, founder of Ivax Corporation, purchased shares of the healthcare company.
I also explained how it seemed that anything Dr.Frost touches turns into gold. His large purchase of shares of Ladenburg Thalmann Financial Services Inc (LTS) catapaulted the stock to multiple returns, and I continue to hold shares in LTS.
Just last Thursday, March 22nd, Dr.Frost and his group purchased controlling shares of Getting Ready Corporation (GTRY.OB) at around $1.25 a share. The stock ended trading on Tuesday at $2.99 a share!
Today, eXegenics (EXEG.OB), which Dr.Frost and his investment group invested in recently, announced that the empty shell company has agreed to merge with two eye disease biotech firms, and form a new company called Opko Corporation.
Opko will be headquartered in Miami, Dr.Frost's business stronghold, and will utilize Acuity Pharmaceuticals and Froptix Corporation's novel eye disease drug programs.
Acuity holds the rights to a drug that successfully completed Phase II clinical trials for wet age-related macular degeneration and diabetic macular edema.
Froptix has a number of drug candidates in preclinical development to treat dry age- related macular degeneration and other ophthalmic diseases. The company also intends to develop complimentary diagnostic tools.
Both companies were privately held.
What really was interesting in Exegenics' press release today was this statement, "...intends to apply to have its shares listed on the American Stock Exchange"
Shares of Exegenics closed Tuesday's trading session at $3.28 a share, after closing at $2.52 the day before. I purchased shares at $1.95 shortly after the closing of Dr.Frost's purchase a couple of months ago.
Here are Dr.Frost stocks I hold:
LTS
bought= $1.09
high= $3.74
CNU
bought= $3.03
high= $3.69
EXEG.OB
bought= $1.95
high= $3.29
Here are some stocks that Dr.Frost has purchased shares of which I do not hold in my portfolio:
Non-Invasive Monitoring Systems Inc.
(NIMU.OB)
Castle Brands
(ROX)
Cellular Technical Services Co.
(CTSC.OB)
Getting Ready Corporation
(GTRY.OB)
Source: BioHealhInvestor.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
![]()
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]












<< My Home | TheMoneyBlogs Home